Credit Suisse’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-44,808
| Closed | -$1.59M | – | 3206 |
|
|
2023
Q1 | $1.59M | Buy |
44,808
+39,349
| +721% | +$1.38M | ﹤0.01% | 2012 |
|
|
2022
Q4 | $192K | Sell |
5,459
-4,115
| -43% | -$137K | ﹤0.01% | 3195 |
|
|
2022
Q3 | $282K | Buy |
9,574
+3,374
| +54% | +$128K | ﹤0.01% | 3108 |
|
|
2022
Q2 | $337K | Sell |
6,200
-23,569
| -79% | -$1.3M | ﹤0.01% | 3096 |
|
|
2022
Q1 | $1.62M | Sell |
29,769
-34,813
| -54% | -$1.89M | ﹤0.01% | 2222 |
|
|
2021
Q4 | $3.56M | Sell |
64,582
-172,038
| -73% | -$8.95M | ﹤0.01% | 2306 |
|
|
2021
Q3 | $11.3M | Buy |
236,620
+28,764
| +14% | +$1.44M | 0.01% | 1460 |
|
|
2021
Q2 | $10.4M | Sell |
207,856
-1,545,150
| -88% | -$74.2M | 0.01% | 1542 |
|
|
2021
Q1 | $78.2M | Buy |
1,753,006
+1,719,224
| +5,089% | +$78M | 0.04% | 512 |
|
|
2020
Q4 | $1.55M | Sell |
33,782
-8,435
| -20% | -$387K | ﹤0.01% | 3018 |
|
|
2020
Q3 | $1.99M | Buy |
42,217
+12,274
| +41% | +$615K | ﹤0.01% | 2429 |
|
|
2020
Q2 | $1.53M | Sell |
29,943
-658,400
| -96% | -$33.8M | ﹤0.01% | 2597 |
|
|
2020
Q1 | $32.6M | Buy |
688,343
+411,837
| +149% | +$22M | 0.03% | 599 |
|
|
2019
Q4 | $16.2M | Buy |
276,506
+192,544
| +229% | +$10.7M | 0.01% | 1153 |
|
|
2019
Q3 | $4.48M | Buy |
83,962
+3,086
| +4% | +$159K | ﹤0.01% | 1835 |
|
|
2019
Q2 | $4.05M | Buy |
80,876
+76,031
| +1,569% | +$3.82M | ﹤0.01% | 1911 |
|
|
2019
Q1 | $253K | Sell |
4,845
-1,376
| -22% | -$68.8K | ﹤0.01% | 3680 |
|
|
2018
Q4 | $297K | Sell |
6,221
-122,774
| -95% | -$6.05M | ﹤0.01% | 3520 |
|
|
2018
Q3 | $6.48M | Buy |
128,995
+8,920
| +7% | +$453K | 0.01% | 1538 |
|
|
2018
Q2 | $6.05M | Sell |
120,075
-8,058
| -6% | -$406K | 0.01% | 1602 |
|
|
2018
Q1 | $6.26M | Sell |
128,133
-119,570
| -48% | -$5.57M | 0.01% | 1552 |
|
|
2017
Q4 | $11M | Buy |
247,703
+168,037
| +211% | +$7.76M | 0.01% | 1227 |
|
|
2017
Q3 | $4.04M | Sell |
79,666
-8,918
| -10% | -$452K | ﹤0.01% | 1939 |
|
|
2017
Q2 | $4.78M | Buy |
88,584
+14,821
| +20% | +$790K | ﹤0.01% | 1656 |
|
|
2017
Q1 | $3.89M | Sell |
73,763
-84,620
| -53% | -$4.29M | ﹤0.01% | 1835 |
|
|
2016
Q4 | $7.63M | Buy |
158,383
+104,170
| +192% | +$5.15M | 0.01% | 1379 |
|
|
2016
Q3 | $2.92M | Buy |
54,213
+19,615
| +57% | +$1.08M | ﹤0.01% | 2102 |
|
|
2016
Q2 | $1.87M | Sell |
34,598
-52,196
| -60% | -$2.75M | ﹤0.01% | 2376 |
|
|
2016
Q1 | $4.4M | Sell |
86,794
-65,986
| -43% | -$3.29M | 0.01% | 1623 |
|
|
2015
Q4 | $7.71M | Buy |
152,780
+102,343
| +203% | +$5.22M | 0.01% | 1304 |
|
|
2015
Q3 | $2.42M | Sell |
50,437
-43,972
| -47% | -$2.29M | ﹤0.01% | 2106 |
|
|
2015
Q2 | $4.92M | Sell |
94,409
-19,066
| -17% | -$1.07M | ﹤0.01% | 1751 |
|
|
2015
Q1 | $6.55M | Sell |
113,475
-40,057
| -26% | -$2.3M | 0.01% | 1463 |
|
|
2014
Q4 | $8.2M | Sell |
153,532
-18,491
| -11% | -$1.03M | 0.01% | 1409 |
|
|
2014
Q3 | $9.88M | Buy |
172,023
+94,353
| +121% | +$5.78M | 0.01% | 1293 |
|
|
2014
Q2 | $5.19M | Sell |
77,670
-1,447
| -2% | -$97.9K | ﹤0.01% | 1925 |
|
|
2014
Q1 | $5.28M | Sell |
79,117
-21,893
| -22% | -$1.48M | 0.01% | 1706 |
|
|
2013
Q4 | $6.74M | Sell |
101,010
-12,633
| -11% | -$819K | 0.01% | 1584 |
|
|
2013
Q3 | $7.13M | Buy |
113,643
+23,128
| +26% | +$1.49M | 0.01% | 1365 |
|
|
2013
Q2 | $5.65M | Buy |
+90,515
| New | +$5.74M | 0.01% | 1478 |
|
Other funds holding GSK
JEST
Credit Suisse's GSK Position: Q2 2023 in Review
Credit Suisse sold out of GSK (GSK) in Q2 2023, closing a stake of 44,808 shares — an estimated $1.59M sold.
Credit Suisse first reported a position in GSK in Q2 2013 and held it in 40 quarters. The position peaked at $78.2M in Q1 2021. 827 funds tracked by Wall St. Rank hold GSK as of Q2 2023.
- Credit Suisse reported no remaining GSK position as of Q2 2023 after selling out during the quarter.
- Credit Suisse sold 44,808 GSK shares in Q2 2023, an estimated $1.59M.
- Credit Suisse first reported a position in GSK in Q2 2013 and held it in 40 quarters.
- Credit Suisse's GSK position peaked at $78.2M in Q1 2021.
- 827 funds tracked by Wall St. Rank held GSK as of Q2 2023.
Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.